Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine in adolescent schizophrenia
NCT03817502Phase 3Recruiting
- Sponsor
- Gedeon Richter Plc
- Start
- Jun 2019
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of cariprazine in schizophrenia (3 arms), sponsored by Gedeon Richter Plc. Primary endpoint: Positive and Negative Syndrome Scale Total at 6 weeks. Started Jun 2019; status: recruiting.
02
Drugs
cariprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03817502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817502.